This company listing is no longer active
Resumen de acción PJ2
Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Competidores de Liminal BioSciences Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €3.80 |
| 52 Week High | €5.32 |
| 52 Week Low | €0.065 |
| Beta | 30.72 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -0.73% |
| 3 Year Change | -94.79% |
| 5 Year Change | -99.92% |
| Change since IPO | -99.81% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| PJ2 | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | 0% | 1.8% | 1.1% |
| 1Y | -0.7% | -23.5% | 1.9% |
Rentabilidad vs. Industria: PJ2 exceeded the German Biotechs industry which returned -7.6% over the past year.
Rentabilidad vs. Mercado: PJ2 exceeded the German Market which returned -4.5% over the past year.
Volatilidad de los precios
| PJ2 volatility | |
|---|---|
| PJ2 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: PJ2 has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: Insufficient data to determine PJ2's volatility change over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1994 | n/a | Bruce Pritchard | www.liminalbiosciences.com |
Resumen de fundamentos de Liminal BioSciences Inc.
| Estadísticas fundamentales de PJ2 | |
|---|---|
| Capitalización bursátil | €11.80m |
| Beneficios(TTM) | -€19.54m |
| Ingresos (TTM) | €269.81k |
43.7x
Ratio precio-ventas (PS)-0.6x
Ratio precio-beneficio (PE)¿Está PJ2 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PJ2 | |
|---|---|
| Ingresos | CA$401.00k |
| Coste de los ingresos | CA$15.30m |
| Beneficio bruto | -CA$14.90m |
| Otros gastos | CA$14.14m |
| Beneficios | -CA$29.04m |
Últimos beneficios comunicados
Dec 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -9.35 |
| Margen bruto | -3,714.96% |
| Margen de beneficio neto | -7,241.40% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado PJ2 a largo plazo?
Ver rendimiento histórico y comparativa